Blocker-SELEX: A Structure-guided Strategy for Developing Inhibitory Aptamers Disrupting Undruggable Transcription Factor Interactions

Tongqing Li,Xueying Liu,Sheyu Zhang,Yu Hou,Yuchao Zhang,Guoyan Luo,Xun Zhu,Yanxin Tao,Mengyang Fan,Chulin Sha,Ailan Lin,Jingjing Qin,Weichang Chen,Ting Fu,Yong Wei,Qin Wu,Weihong Tan

DOI: https://doi.org/10.1101/2024.01.09.574928

2024-01-10

Abstract:Despite the well-established significance of transcription factors (TFs) in pathogenesis, their utilization as pharmacological targets has been limited by the inherent challenges associated with modulating their protein-protein and protein-DNA interactions. The lack of defined small-molecule binding pockets and the nuclear localization of TFs do not favor the use of small-molecule inhibitors, or neutral antibodies, in blocking TF interactions. Aptamers are short oligonucleotides exhibiting high affinity and specificity for a diverse range of targets. Large molecular weights, expansive blocking surfaces and efficient cellular internalization make aptamers a compelling molecular tool for use as traditional TF interaction modulators. Here, we report a structure-guided design strategy called Blocker-SELEX to develop inhibitory aptamers (iAptamer) that selectively block TF interactions. Our approach led to the discovery of iAptamers that cooperatively disrupts SCAF4/SCAF8-RNA Polymerase II (RNAP2) interactions, thereby dysregulating RNAP2-dependent gene expression and splicing and, in turn, leading to the impairment of cell proliferation. This approach was further applied to develop iAptamers to efficiently block WDR5-MYC interaction with a nexus in cancer. Taken together, our study highlights the potential of Blocker-SELEX in developing iAptamers that effectively disrupt potentially pathogenic TF interactions with attendant implications for iAptamers as chemical tools for use in the study of biological functions of TF interactions, but also for potential use in nucleic acids drug discovery.

Biochemistry

What problem does this paper attempt to address?

The paper aims to address the inherent challenges faced when targeting transcription factors (TFs) as drug targets, particularly in regulating their protein-protein and protein-DNA interactions. Specifically, the paper proposes a structure-guided design strategy called Blocker-SELEX for developing inhibitory aptamers (iAptamer) that can specifically block transcription factor interactions. This strategy involves screening a single-stranded DNA library to identify sequences that can effectively disrupt the interface of specific transcription factor complexes and further optimizing these sequences to enhance their affinity and competitive inhibition effects.

The paper primarily addresses the following issues:
1. **Development of new tools**: Since most traditional small molecule inhibitors cannot effectively target the interaction sites of transcription factors, the paper develops inhibitory aptamers as an alternative solution.
2. **Validation of strategy effectiveness**: The Blocker-SELEX strategy successfully designed iAptamers that can inhibit the interaction between SCAF4/SCAF8 and RNA polymerase II (RNAP2), demonstrating the effectiveness of the strategy.
3. **Biological function research**: These iAptamers can not only serve as chemical tools for studying the biological functions of transcription factor interactions but also have potential value in nucleic acid drug development.

In summary, this research provides a new solution for targeting the challenging transcription factor interactions, showcasing the potential applications of inhibitory aptamers in biomedical research and therapy.